Group 1 - The healthcare sector in Hong Kong saw over 60% of its 290 stocks decline, with 61 stocks dropping more than 4% on February 26 [2] - The stocks of Dechra Pharmaceuticals (06996.HK), BeiGene (06160.HK), and WuXi AppTec (02268.HK) led the declines, falling by 10.44%, 9.16%, and 8.69% respectively [2] - BeiGene's market capitalization fell below 300 billion HKD, closing at 299.5 billion HKD on February 26 [2] Group 2 - BeiGene is set to announce its financial performance for the fourth quarter and the full year of 2025 after the market close on February 26, according to previous announcements [4] - As of the time of reporting, BeiGene had not yet released its financial report [4]

中国经济网北京2月26日讯 百济神州(688235.SH)今日收报263.44元，跌幅5.65%。 东吴证券股份有限公司研究员朱国广、张翀翯2025年9月2日发布研报《百济神州(688235)2025年中报点 评：业绩超预期 上调全年业绩指引》称，维持百济神州"买入"评级。 百济神州2025年9月2日盘中股价创下历史高点346.00元。 东莞证券股份有限公司研究员谢雄雄2025年9月2日发布研报《百济神州(688235)：Q2业绩保持稳定增 长》称，给予对公司"增持"评级。 ...

2月26日下午，港股医疗保健板块内的290只个股，六成以上出现下跌，其中有61只个股跌幅超过4%， 其中德琪医药（06996.HK）、百济神州（06160.HK）、药明合联（02268.HK）三只个股跌幅领衔，分 别大跌10.44%、9.16%、8.69%。 按照百济神州前期的公告，该公司将于2月26日港股股价收盘后公布其根据美国公认会计原则及美国证 券交易委员会适用规则编制的2025年第四季度及全年的财务业绩。 截至记者发稿之际，百济神州尚未发布财报。 伴随着股价大跌，百济神州2月26日在港股市场的市值跌破3000亿港元，最后报2995亿港元。 | 百济神州 (06160.HK) | | C | | | --- | --- | --- | --- | | 已收盘 02-26 16:08:14 | | | | | 港交所规定,港股基础行情需手动下拉刷新 | | | × | | 194.400 HKD | | | ☆ 窝 通 BMP 竞 : | | -19.600 -9.16% 生物技术 -5.96% > | | | | | 今 开 最 高 213.400 | 213.400 | | 成交量 601.23万股 ...

2月26日下午，港股医疗保健板块内的290只个股，六成以上出现下跌，其中有61只个股跌幅超过4%， 其中德琪医药（06996.HK）、百济神州（06160.HK）、药明合联（02268.HK）三只个股跌幅领衔，分 别大跌10.44%、9.16%、8.69%。 伴随着股价大跌，百济神州2月26日在港股市场的市值跌破3000亿港元，最后报2995亿港元。 | 自杀神州(06160.HK) | | | | | --- | --- | --- | --- | | 已收盘 02-26 16:08:14 | | | | | 港交所规定,港股基础行情需手动下拉刷新 | | | | | 194.400 HKD | | gr | 窝 通 BMP | | -19.600 -9.16% 生物技术 -5.96% > | | | | | 今 开 最 高 213.400 | 213.400 | | 成交量 601.23万股 | | 昨 收 最 低 194.000 | 214.000 | | 成交额 12.06亿 | | 换手率 市盈 TM (2 561.39 | 0.42% | | 总市值 ▼ 2995.08亿 | | 量 比 而容动 ...

港股创新药板块持续走弱，百济神州跌超8%，药明生物跌超7%，泰格医药、康龙化成、诺诚健华跟 跌。 ...

Group 1 - The core viewpoint of the article highlights a significant decline in Hong Kong pharmaceutical stocks, particularly in the innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137) both dropping over 2% [1][2] - The leading company, BeiGene, experienced a drop of over 6% and is set to disclose its 2025 financial report today. It holds significant weight in the aforementioned ETFs, accounting for 11.27% and 2.13% of their respective portfolios [2] - According to Kaiyuan Securities, the Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," indicating a shift from pipeline expectations to performance realization. The innovative drug sector has seen a two-quarter correction, but many quality stocks are now considered to have attractive valuations, suggesting increased attention is warranted [2] Group 2 - The article suggests that investors should consider low-positioned opportunities in Hong Kong pharmaceutical stocks through ETFs for higher efficiency and flexibility, particularly recommending the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds [2] - The Hong Kong Stock Connect Medical ETF (159137) is recommended for its focus on medical innovation, covering hot concepts such as brain-computer interfaces, AI healthcare, and internet pharmacies, while also encompassing leading companies across the entire innovative drug supply chain [2]

Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene was established on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - Morgan Stanley's fund holds a significant position in BeiGene, with the Morgan Stanley Health Industry Mixed A Fund (002708) maintaining 231,800 shares, unchanged from the previous period, representing 4.12% of the fund's net value [2] - The Morgan Stanley Health Industry Mixed A Fund has a total size of 1.423 billion CNY and has experienced a loss of 0.47% this year, ranking 8462 out of 8887 in its category, while its one-year return is 0.89%, ranking 7892 out of 8134 [2] Group 3 - The fund manager of the Morgan Stanley Health Industry Mixed A Fund is Wang Dapeng, who has been in the position for 11 years and 39 days, with the fund's total asset size at 1.997 billion CNY. The best return during his tenure is 70.7%, while the worst return is -50.91% [3]

Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene, established on October 28, 2010, is located in Beijing and specializes in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of major fund holdings, CITIC Prudential Fund has a significant position in BeiGene, holding 11,900 shares in its CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A, which accounts for 1.99% of the fund's net value, ranking it as the tenth largest holding [2] - The CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A was established on January 1, 2021, with a current size of 147 million CNY, and has reported a year-to-date return of 1.77% and a one-year return of 16.18% [2] - The fund manager, Huang Zhi, has been in the position for 7 years and 219 days, overseeing assets totaling 4.418 billion CNY, with the best fund return during his tenure being 146.63% and the worst being -26.08% [2]

Group 1 - The Livermore Chinese concept stock index experienced a slight decline of 0.1% at the beginning of trading on February 25 [1] - Among the constituent stocks, BeiGene saw a drop of over 3% [1] - Tencent Music, Xpeng Motors, and NetEase each fell by more than 2% [1]

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]